- Home
- CDTX vs ZNTL Comparison
CDTX vs ZNTL Comparison
Compare CDTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- ZNTL
- Stock Information
- Founded
- CDTX 2012
- ZNTL 2014
- Country
- CDTX United States
- ZNTL United States
- Employees
- CDTX N/A
- ZNTL N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CDTX Health Care
- ZNTL Health Care
- Exchange
- CDTX Nasdaq
- ZNTL Nasdaq
- Market Cap
- CDTX 980.1M
- ZNTL 105.8M
- IPO Year
- CDTX 2015
- ZNTL 2020
- Fundamental
- Price
- CDTX $47.87
- ZNTL $1.24
- Analyst Decision
- CDTX Strong Buy
- ZNTL Buy
- Analyst Count
- CDTX 11
- ZNTL 7
- Target Price
- CDTX $52.11
- ZNTL $8.60
- AVG Volume (30 Days)
- CDTX 1.3M
- ZNTL 1.4M
- Earning Date
- CDTX 08-12-2025
- ZNTL 08-08-2025
- Dividend Yield
- CDTX N/A
- ZNTL N/A
- EPS Growth
- CDTX N/A
- ZNTL N/A
- EPS
- CDTX N/A
- ZNTL N/A
- Revenue
- CDTX $302,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- CDTX N/A
- ZNTL N/A
- Revenue Next Year
- CDTX N/A
- ZNTL N/A
- P/E Ratio
- CDTX N/A
- ZNTL N/A
- Revenue Growth
- CDTX N/A
- ZNTL N/A
- 52 Week Low
- CDTX $10.14
- ZNTL $1.01
- 52 Week High
- CDTX $56.83
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- CDTX 77.18
- ZNTL 44.51
- Support Level
- CDTX $45.42
- ZNTL $1.13
- Resistance Level
- CDTX $50.48
- ZNTL $1.39
- Average True Range (ATR)
- CDTX 4.17
- ZNTL 0.12
- MACD
- CDTX 1.97
- ZNTL -0.03
- Stochastic Oscillator
- CDTX 75.57
- ZNTL 26.83
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.